Ibex Medical Analytics announced today that a study of its Galen Breast diagnostic solution delivered positive outcomes.
Tel Aviv, Israel-based Ibex designed its Galen platform to support pathologists in diagnosing breast, prostate, and gastric biopsies.
Galen uses AI and machine learning technology based on hundreds of thousands of image samples scanned from biopsy slides through digital pathology.
The AI technology provides accuracy, speed and objectivity, Ibex said in a news release. It aims to improve the quality of diagnosis, user experience, operational efficiency and patient outcomes.
Galen Breast, which holds CE mark approval, is generally available to laboratories and hospitals across Europe.
In a blinded, multi-site clinical study in France and Maccabi Healthcare Services in Israel, Galen Breast produced strong outcomes. The study evaluated the performance of pathologists who used Ibex AI for diagnosing breast biopsies. It compare…